- Neuralink, the neurotech startup co-founded by Elon Musk, announced Thursday it has received approval from the FDA to conduct its first in-human clinical study.
- The implant aims to help patients with severe paralysis regain their ability to communicate by controlling external technologies using only neural signals.
- The extent of the approved trial is not known.
- Neuralink said in a tweet that patient recruitment for its clinical trial is not open yet.
